ORIGINAL RESEARCH
Therapeutic efficacy of N-cholinolitic drug N,N-Diethyl-5,5-diphenyl-2-pentynylamine in models of non-cardiogenic pulmonary edema
Golikov Research Clinical Center of Toxicology of the Federal Medical and Biological Agency, Saint-Petersburg, Russia
Correspondence should be addressed: Konstantin A. Krasnov
Bekhtereva, 1/2, k. 54, Saint-Petersburg, 199106, Russia; ur.liam@xot_vonsark
Funding: state contract № 2124388100122000000000000/64.020.21.9 of 2 November 2021, “Developing New Antidote Medications for Treatment of Toxic Pulmonary Edema” (code: “Tuman”)
Author contribution: Melikhova MV — assessment of the animals’ physiological state, data processing and interpretation; Krasnov КА — modeling of toxic pulmonary edema in animals, prepress manuscript preparation; Rozhko МА — drug administration through inhalation and monitoring of external respiration parameters in animals; Lapina NV — general management; Krasnova АА — lung gravimetry in animals.
Compliance with ethical standards: all the procedures involving model animals were performed in accordance with the principles of Good Laboratory Practice and the Directive 2010/63/EU of the European Parliament and (2010) on the protection of animals used for scientific purposes.